Page 2 - Sudocetaxel Zendusortide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action

Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Philippe dubucJulie schneidermanChristian marsolaisBorhane annabiChemistry departmentTheratechnologies incCommunications corporate affairsSenior vice presidentChief medical officerCancer preventionSudocetaxel zendusortideFast trackForward looking statementsLooking statementsAnnual information formVice president

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesChristian marsolaisPhilippe dubucJulie schneidermanSudocetaxel zendusortideIra winerKarmanos cancer centerCommunications corporate affairsTheratechnologies incAmerican society of clinical oncologyDrug administrationCompletes enrollmentFirst six patientsUpdated phaseAdvanced ovarianSenior vice president

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel

Milestone for Company’s lead peptide-drug conjugate candidate follows FDA acceptance of protocol amendment for Phase 1 study on June 2, 2023

United statesJulie schneidermanIra winerChristian marsolaisPhilippe dubucDrug administrationAmerican society of clinical oncologyMilestone for companyKarmanos cancer centerCommunications corporate affairsTheratechnologies incSenior vice presidentChief medical officerGynecologic oncologyAmerican societySudocetaxel zendusortide

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesJulie schneidermanIra winerChristian marsolaisPhilippe dubucSudocetaxel zendusortideKarmanos cancer centerDrug administrationTheratechnologies incAmerican society of clinical oncologyMilestone for companyCommunications corporate affairsAnnounces dosingFirst patientUpdated clinical trialAdvanced ovarian

Theratechnologies Announces All U S Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide

MONTREAL, Aug. 30, 2023 (GLOBE NEWSWIRE) Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmac.

Julie schneidermanPhilippe dubucSudocetaxel zendusortideCommunications corporate affairsTheratechnologies incCompany phaseForward looking statementsLooking statementsAnnual information formVice presidentChief financial officer